Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function.

被引：0
|
作者：
Weber, Donna
Wang, Michael
Chen, Christine
Belch, Andrew
Stadtmauer, Edward A.
Niesvisky, Ruben
Yu, Zhinuan
Olesnyckyj, Marta
Zeldis, Jerome
Knight, Robert D.
Dimopoulos, Meletios
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX USA
[2] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[3] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[4] Univ Penn, Philadelphia, PA 19104 USA
[5] Cornell Univ, Presbyterian Hosp, New York, NY USA
[6] Celgene Corp, Summit, NJ USA
[7] Univ Athens, Sch Med, Dept Therapeut, Kifisia, Greece
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3547
引用
收藏
页码：1012A / 1013A
页数：2
相关论文
共 50 条
  • [1] Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of a North American phase III study (MM-009).
    Weber, D. M.
    Chen, C.
    Niesvizky, R.
    Wang, M.
    Belch, A.
    Stadtmauer, E.
    Yu, Z.
    Olesnyckyj, M.
    Zeldis, J.
    Knight, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 427S - 427S
  • [2] Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
    M A Dimopoulos
    C Chen
    A Spencer
    R Niesvizky
    M Attal
    E A Stadtmauer
    M T Petrucci
    Z Yu
    M Olesnyckyj
    J B Zeldis
    R D Knight
    D M Weber
    Leukemia, 2009, 23 : 2147 - 2152
  • [3] Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
    Dimopoulos, M. A.
    Chen, C.
    Spencer, A.
    Niesvizky, R.
    Attal, M.
    Stadtmauer, E. A.
    Petrucci, M. T.
    Yu, Z.
    Olesnyckyj, M.
    Zeldis, J. B.
    Knight, R. D.
    Weber, D. M.
    LEUKEMIA, 2009, 23 (11) : 2147 - 2152
  • [4] Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): Results of a phase 3 study (MM-010).
    Dimopoulos, MA
    Spencer, A
    Attal, M
    Prince, M
    Harousseau, JL
    Dmoszynska, A
    Yu, ZU
    Olesnyckyj, M
    Zeldis, J
    Knight, R
    BLOOD, 2005, 106 (11) : 6A - 7A
  • [5] Analysis of renal impairment in MM-003, a phase III study of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in refractory or relapsed and refractory multiple myeloma
    Weisel, Katja C.
    Dimopoulos, Meletios A.
    Moreau, Philippe
    Lacy, Martha Q.
    Song, Kevin W.
    Delforge, Michel
    Karlin, Lionel
    Goldschmidt, Hartmut
    Banos, Anne
    Oriol, Albert
    Alegre, Adrian
    Chen, Christine
    Cavo, Michele
    Garderet, Laurent
    Ivanova, Valentina
    Martinez-Lopez, Joaquin
    Knop, Stefan
    Yu, Xin
    Hong, Kevin
    Sternas, Lars
    Jacques, Christian
    Zaki, Mohamed H.
    Miguel, Jesus San
    HAEMATOLOGICA, 2016, 101 (07) : 872 - 878
  • [6] THE STRATUS TRIAL (MM-010): ANALYSIS OF THE ITALIAN SUBGROUP OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE
    Cavo, M.
    Corradini, P.
    Di Raimondo, F.
    Vacca, A.
    Petrini, M.
    Cafro, A. M.
    di Toritto, T. Caravita
    Offidani, M.
    Semenzato, G.
    Zambello, R.
    Lazzaro, A.
    Patriarca, F.
    Petrucci, M. T.
    Rodeghiero, F.
    Simcock, M.
    Slaughter, A.
    Herring, J.
    Peluso, T.
    Palumbo, A.
    HAEMATOLOGICA, 2016, 101 : 795 - 795
  • [7] OVERALL SURVIVAL OF PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: ADJUSTING FOR CROSSOVER IN THE MM-003 TRIAL FOR POMALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE
    Morgan, G.
    San Miguel, J. F.
    Dhanasiri, S.
    Lee, D.
    Palumbo, A.
    Facon, T.
    Zaki, M.
    Yu, X.
    Sternas, L.
    Jacques, C.
    Weisel, K.
    Offner, F.
    Dimopoulos, M.
    HAEMATOLOGICA, 2014, 99 : 365 - 366
  • [8] Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
    San Miguel, Jesus
    Weisel, Katja
    Moreau, Philippe
    Lacy, Martha
    Song, Kevin
    Delforge, Michel
    Karlin, Lionel
    Goldschmidt, Hartmut
    Banos, Anne
    Oriol, Albert
    Alegre, Adrian
    Chen, Christine
    Cavo, Michele
    Garderet, Laurent
    Ivanova, Valentina
    Martinez-Lopez, Joaquin
    Belch, Andrew
    Palumbo, Antonio
    Schey, Stephen
    Sonneveld, Pieter
    Yu, Xin
    Sternas, Lars
    Jacques, Christian
    Zaki, Mohamed
    Dimopoulos, Meletios
    LANCET ONCOLOGY, 2013, 14 (11): : 1055 - 1066
  • [9] ANALYSIS OF PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN THE PHASE 3B STRATUS TRIAL (MM-010)
    Weisel, K.
    Dimopoulos, M. A.
    Palumbo, A.
    Corradini, P.
    Cavo, M.
    Delforge, M.
    Ocio, E. M.
    Vacca, A.
    Hansson, M.
    Blanchard, M.
    Milller, N.
    Peluso, T.
    Sternas, L.
    Zaki, M.
    Moreau, P.
    HAEMATOLOGICA, 2015, 100 : 89 - 90
  • [10] Dexamethasone dose adjustments seem to result in better efficacy and improved tolerability in patients with relapsed/refractory multiple myeloma who are treated with lenalidomide/dexamethasone (MM009/010 sub-analysis)
    Miguel, Jesus F. San
    Dimopoulos, Meletios
    Weber, Donna
    Olesnyckyj, Marta
    Yu, Zhinuan
    Zeldis, Jerome
    Night, Robert K.
    Raijkumar, Vincent
    BLOOD, 2007, 110 (11) : 796A - 796A
12345